RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

Rachel Adams; Nicole Daly; Elizabeth Robertson; Giuseppe N. Giordano

doi:10.1002/edm2.207

RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

Rachel Adams, Nicole Daly, Elizabeth Robertson, Giuseppe N. Giordano

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

Originalspråk	engelska
Tidskrift	Endocrinology, Diabetes and Metabolism
Volym	4
Utgåva	2
Tidigt onlinedatum	2020 dec. 6
DOI	https://doi.org/10.1002/edm2.207
Status	Published - 2021

Ämnesklassifikation (UKÄ)

Endokrinologi och diabetes

Tillgång till dokument

10.1002/edm2.207

Citera det här

@article{89dd37595a87403a96aa308079027209,

title = "RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes",

abstract = "Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.",

keywords = "biomarkers, disease progression, novel clinical trial design, prediabetes, type 2 diabetes mellitus",

author = "Rachel Adams and Nicole Daly and Elizabeth Robertson and Giordano, {Giuseppe N.}",

year = "2021",

doi = "10.1002/edm2.207",

language = "English",

volume = "4",

journal = "Endocrinology, Diabetes & Metabolism",

issn = "2398-9238",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

TY - JOUR

T1 - RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

AU - Adams, Rachel

AU - Daly, Nicole

AU - Robertson, Elizabeth

AU - Giordano, Giuseppe N.

PY - 2021

Y1 - 2021

N2 - Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

AB - Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

KW - biomarkers

KW - disease progression

KW - novel clinical trial design

KW - prediabetes

KW - type 2 diabetes mellitus

U2 - 10.1002/edm2.207

DO - 10.1002/edm2.207

M3 - Article

C2 - 33855210

AN - SCOPUS:85097246012

VL - 4

JO - Endocrinology, Diabetes & Metabolism

JF - Endocrinology, Diabetes & Metabolism

SN - 2398-9238

IS - 2

ER -

RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Citera det här